This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David J. Goldstein, MD, PhD; Dena E. Marvel, RPh
Eli Lilly and Company Indianapolis, Ind

JAMA. 1993;270(18):2177.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—As of March 31, 1993, our fluoxetine pregnancy database contained 1103 prospectively reported pregnancies. Of these prospective reports, outcomes are available from 544 (59 from clinical trials and 485 from spontaneous reports) of the 761 pregnancies that had potentially reached term. This is a 71% follow-up rate. Of these 544 pregnancies, 91 were electively terminated. Spontaneous abortion was reported in 72 (15.9%). There were two stillbirths. Perinatal major malformations were reported in 13 (3.4%). These malformations were macrostomia, atrial septal defect, bilateral hydroceles, gastrointestinal anomaly, constricted band syndrome, intestinal blockage, ureteral disorder (two cases), trisomy 18, stubbed and missing digits, trisomy 21, abdominal wall defect (in one twin), and hepatoblastoma. Additionally, seven postperinatal malformations were reported. These were pyloric stenosis (two cases), arrhythmia, tracheal malacia (three cases), and volvulus.

Although the fluoxetine-treated population may differ from the general population because of the concomitant use of medications, alcohol . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?